How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Soliris Drug Market
- By Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)
- By Route of Administration: Intravenous Infusion
- By Patient Population: Adult Patients, Pediatric Patients
- By Treatment Setting: Hospital Outpatient, Specialty Clinics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Paroxysmal Nocturnal Hemoglobinuria (PNH) leads By Indication at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 1 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 223 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.151 →
- 11 Company Profiles 1 players: SWOT & benchmarking p.159 →
Full report · locked preview
Everything inside the Soliris Drug Market report
A complete, evidence-based study - 11 chapters and 93 sections covering market size, segmentation across 4 axes, regional analysis and 1 company profiles, forecast to 2033.
Segmentation covered
Indication 4
Route of Administration 1
Patient Population 2
Treatment Setting 2
Companies profiled
Alexion Pharmaceuticals (a subsidiary of AstraZeneca)
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
1 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,055M by 2033 · 9.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Paroxysmal Nocturnal Hemoglobinuria (PNH)64.3
- Atypical Hemolytic Uremic Syndrome (aHUS)11.5
- Generalized Myasthenia Gravis (gMG)9.6
- Neuromyelitis Optica Spectrum Disorder (NMOSD)14.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,436M → $3,334M · 11.1%
Europe$1,001M → $2,029M · 9.2%
Asia Pacific$913.6M → $1,984M · 10.2%
Latin America$565.6M → $1,065M · 8.2%
Middle East and Africa$435.0M → $837.3M · 8.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.552026
9.562027
9.582028
9.582029
9.592030
9.612031
9.622032
9.632033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Alexion Pharmaceuticals (a subsidiary of AstraZeneca)72.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Indication41.4%
Route of Administration22.9%
Patient Population16.4%
Treatment Setting19.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.0
- Europe21.9
- Asia Pacific21.5
- Latin America11.5
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
5 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals (a subsidiary of AstraZeneca) | 94 | 80 | 77 | 89 | 89 | 98 | 88 |
| Market Leader Co | 75 | 90 | 73 | 73 | 78 | 81 | 78 |
| Global Peer Inc | 80 | 79 | 65 | 65 | 74 | 64 | 71 |
| Regional Player | 70 | 66 | 58 | 78 | 70 | 80 | 70 |
| Emerging Challenger | 53 | 64 | 59 | 75 | 69 | 57 | 63 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Alexion Pharmaceuticals (a subsidiary of AstraZeneca)
- Market Leader Co
- Global Peer Inc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals (a subsidiary of AstraZeneca) | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Market Leader Co | ◐ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Global Peer Inc | ✓ | ◐ | ◐ | − | − | ◐ |
| Regional Player | ✓ | ◐ | − | ◐ | ◐ | ✓ |
| Emerging Challenger | − | ◐ | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Alexion Pharmaceuticals (a subsidiary of AstraZeneca)88
2Market Leader Co78
3Global Peer Inc71
4Regional Player70
5Emerging Challenger63
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Alexion Pharmaceuticals (a subsidiary of AstraZeneca)Market Leader Co
Challenger2
Strong scale, closing on the leaders.
Global Peer IncRegional Player
Contender1
Focused players with pockets of strength.
Emerging Challenger
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Indication in North America, then scale across Soliris Drug Market — a $130M beachhead inside a $1.88B market.
Beachhead (SOM)$130Mobtainable near-term
Serviceable (SAM)$731Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Best fit — highest urgency & budget in Indication.
Economic buyer76 fit
Atypical Hemolytic Uremic Syndrome (aHUS)
Strong fit — clear ROI and a fast path to value.
End user69 fit
Generalized Myasthenia Gravis (gMG)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Indication in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Population
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel29%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Indication leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Soliris Drug Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified22%
Evaluation13%
Closed-won7%
$10.8KCAC
$47KLTV
4.3:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Soliris Drug Market is a resilient opportunity — $3.11B by 2033, compounding at 4.4%.
TAM · 2025$2.21Btoday
TAM · 2033$3.11Bforecast
CAGR4.4%2027–2033
Cumulative$23.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.11BTotal addressable market
SAM$1.28BServiceable available market
SOM$256MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.4% CAGR
Demand compounds through 2033, outpacing GDP across Indication.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Indication moving from early to mainstream — durable secular demand.
Consolidation upside
1+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.11BLarge & growingTAM by 2033 at 4.4% CAGR
$1.28BServiceable nowreachable with today’s model
$256MBeachhead winobtainable near-term share
1+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.43BBear2.9% CAGR
$3.11BBase4.4% CAGR
$3.99BBull5.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Soliris Drug Market — a $4.17B market by 2033. Plan: grow share from 9.1% to 14.4%.
Market size · 2033$4.17Btotal addressable
Market CAGR9.5%2027–2033
Target share14.4%from 9.1% today
Revenue ambition$601Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 14.4% | At risk |
| Revenue | $406M | $601M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 29.7% | 43.4% | At risk |
| Customer retention | 87.2% | 92.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Indication
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Indication share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $85M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Indication leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Soliris Drug Market conversation — a $6.19B market you can size, segment and defend in minutes.
Market size · 2033$6.19Btotal opportunity
Growth3.3%CAGR to 2033
Addressable buyers1,039+accounts in scope
Typical ROI5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Indication
Goal Grow share in Indication
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5×return on cost, year one
< 3 mopayback period
$97K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
1+players profiled in this market
Coverage includes
Alexion Pharmaceuticals (a subsidiary of AstraZeneca)
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Soliris Drug Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Soliris Drug Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Pharmaceutical Grade Fish Oil Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportThymopentin Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportSPECT Radiopharmaceuticals Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportHyaluronic Acid (HA) for Medical Market
Market size, share, segmentation and regional forecast.
$660M market · 2025 base year
View report1,3-Dioxane-4-Aceticacid, 6-(Cyanomethyl)-2,2-Dimethyl-, 1,1-Dimethylethyl Ester, (4R,6R) (CAS 125971-94-0) Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View report(3R)-4-Cyano-3-Hydroxybutyric Acid Ethyl Ester (CAS 141942-85-0) Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportAir Jacketed Incubators Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportHuman Activin A Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportActivin A Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportLive Attenuated Vaccines Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportAntiepileptic Drugs Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportCardiac Troponin Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.